Trials / Sponsors / Sierra Oncology LLC - a GSK company
Sierra Oncology LLC - a GSK company
Industry · 19 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 3 | 2020-02-07 |
| Completed | A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Advanced Solid Tumors | Phase 1 / Phase 2 | 2016-07-01 |
| Completed | A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) | Phase 1 / Phase 2 | 2016-07-01 |
| Completed | Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV) Myelofibrosis, Postessential Thrombocythemia (Post-ET) Myelofibrosis | Phase 2 | 2016-01-29 |
| Terminated | PNT2258 for Treatment of Patients With Richter's Transformation (Brighton) Richter's Transformation | Phase 2 | 2015-08-01 |
| Terminated | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small C Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer | Phase 1 | 2015-03-11 |
| Completed | PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) Lymphoma, Diffuse Large B-Cell | Phase 2 | 2014-12-01 |
| Terminated | Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreati Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | 2014-11-05 |
| Terminated | Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine K EGFR Mutated EGFR TKI Naive Metastatic NSCLC | Phase 1 | 2014-10-16 |
| Completed | Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myel Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Phase 3 | 2014-06-19 |
| Terminated | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | 2014-06-02 |
| Completed | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera My Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 2 | 2014-04-30 |
| Terminated | Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Polycythemia Vera, Essential Thrombocythemia | Phase 2 | 2014-02-19 |
| Completed | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 3 | 2013-12-06 |
| Completed | Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma Lymphoma, Non-Hodgkin's | Phase 2 | 2012-11-01 |
| Completed | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemi Primary Myelofibrosis, Post-Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis | Phase 1 / Phase 2 | 2011-08-01 |
| Completed | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 2 | 2010-11-01 |
| Completed | A Study of PNT2258 in Patients With Advanced Solid Tumors Cancer, Lymphoma, Prostate Cancer | Phase 1 | 2010-08-01 |
| Completed | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-esse Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis | Phase 1 / Phase 2 | 2009-11-01 |